BCL2 and acute myeloid leukemia: Our previous work and other reports have demonstrated that AML cells are sensitive to glutamine withdrawal and interference with glutamine metabolism [24,25], and that targeting glutaminolysis synergizes with BCL-2 inhibition [26].